Insilico Medicine's PandaOmics Enables AI-Driven Indication Expansion Strategy for ...

THPharm and Insilico Medicine are collaborating on a bio-AI-driven reverse engineering drug development strategy using PandaOmics to expand indications for metabolic disease drugs, focusing initially on diseases like heart failure, fatty liver disease, and obesity. This approach leverages existing non-clinical data and AI analysis to reduce risks and prioritise the most promising drug development pathways for Phase 3 and follow-up clinical trials.

This Wire brief sits within Fusion42's coverage of Drug Discovery, AI Frontier Models and Biotech.